Ruzasvir
Modify Date: 2024-01-15 12:10:05
Ruzasvir structure
|
Common Name | Ruzasvir | ||
|---|---|---|---|---|
| CAS Number | 1613081-64-3 | Molecular Weight | 947.087 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C49H55FN10O7S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of RuzasvirA potent, pan-genotype HCV NS5A inhibitor with replicon EC90 of 0.003, 0.016, 0.067, 0.036, 0.007, and 0.007 nM for GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a, and Gt4a, respectively. HCV Infection Phase 2 Clinical |
| Name | ruzasvir |
|---|---|
| Synonym | More Synonyms |
| Description | A potent, pan-genotype HCV NS5A inhibitor with replicon EC90 of 0.003, 0.016, 0.067, 0.036, 0.007, and 0.007 nM for GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a, and Gt4a, respectively. HCV Infection Phase 2 Clinical |
|---|---|
| References | References 1. Tong L, et al. J Med Chem. 2017 Jan 12;60(1):290-306. 2. Wyles D, et al. Hepatology. 2017 Dec;66(6):1794-1804. 3. Lawitz E, et al. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):814-823. View Related Products by Target HCV HCV Infection |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Molecular Formula | C49H55FN10O7S |
| Molecular Weight | 947.087 |
| Exact Mass | 946.395996 |
| LogP | 6.30 |
| Index of Refraction | 1.742 |
| LX752BD95Y |
| UNII:LX752BD95Y |
| Carbamic acid, N,N'-[[(6S)-6-(2-cyclopropyl-5-thiazolyl)-1-fluoro-6H-indolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis[1H-imidazole-5,2-diyl(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis-, dimethyl ester |
| Methyl {(2S)-1-[(2S)-2-{5-[(6S)-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-3-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-pyrrolidinyl]-1H-imidazol-5-yl}indolo[1,2-c][1,3]benzoxazin-10-yl]-1H-imidazol-2-yl}-1-pyrrolidinyl]-3-methyl-1-oxo-2-butanyl}carbamate |
| ruzasvir |
| MFCD30829910 |